Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- Revolution Medicines, Inc.
- Study ID
- NCT07621718
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma Metastatic
- Pancreatic Adenosquamous Carcinoma
- Pancreatic Cancer
- Pancreatic Cancer Metastatic
- Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Zoldonrasib — DRUGoral tablets
- Placebo — DRUGoral tablets
- Oxaliplatin — DRUGIV infusion
- Leucovorin (Calcium Folinate) — DRUGIV infusion
- 5-Fluorouracil — DRUGIV infusion
- Irinotecan — DRUGIV infusion
- Gemcitabine (GEM) — DRUGIV infusion
- Nab-paclitaxel — DRUGIV infusion
Study Details
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
Key Dates
- First listed
- Jun 2, 2026
- Start date
- May 22, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 30, 2028
- Completion
- Apr 22, 2030
Study Design
- Enrollment
- 670 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: zoldonrasib + chemotherapystudy drug in combination with Investigator choice chemotherapy (mFFX or GnP)
- Placebo Comparator: Arm B: placebo + chemotherapyplacebo in combination with Investigator choice chemotherapy (mFFX or GnP)
Primary Outcome Measure
Progression free survival (PFS) [ Time Frame: Up to approximately 4 years ]
Central Contacts
- Revolution Medicines Study Director1-844-2-REVMED
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | |
| Piedmont Healthcare | Atlanta | Georgia | 30318 | |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | |
| Johns Hopkins University | Baltimore | Maryland | 21287 |
Find similar trials in Tampa, FL
By condition
By specialty
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the PancreasPHASE2 · Recruiting · Proton Collaborative Group · Warrenville, Illinois
- American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) RegistryRecruiting · University of Louisville · Birmingham, Alabama